Treatment | N | Total CUA cases | N | Non dialysis cases | N | Dialysis cases | N | Dialysis controls | P Value |
---|---|---|---|---|---|---|---|---|---|
25-hydroxyvitamin D | 89 | 53 (59.6%) | 19 | 11 (57.9%) | 70 | 42 (60.0%) | 137 | 89 (65.0%) | 0.48 |
Active vitamin D | 89 | 19 (21.4%) | 19 | 3 (15.8%) | 70 | 16 (22.9%) | 137 | 31 (22.6%) | 0.97 |
Calcium-based phosphate binders | 89 | 47 (52.8%) | 19 | 6 (31.6%) | 70 | 41 (58.6%) | 137 | 60 (43.8%) | 0.04 |
Non calcium-based phosphate binders | 89 | 47 (52.8%) | 19 | 4 (21.1%) | 70 | 43 (61.4%) | 137 | 76 (55.6%) | 0.41 |
Sevelamer | 89 | 37 (41.6%) | 19 | 4 (21.1%) | 70 | 33 (47.1%) | 137 | 58 (41.4%) | 0.43 |
Lanthanum carbonate | 89 | 12 (13.5%) | 19 | 1 (5.3%) | 70 | 11 (15.7%) | 137 | 19 (13.6%) | 0.68 |
Cinacalcet | 89 | 17 (19.1%) | 19 | 1 (5.3%) | 70 | 16 (22.9%) | 136 | 26 (19.1%) | 0.53 |
Betablocker | 89 | 54 (60.7%) | 19 | 15 (79.0%) | 70 | 39 (55.7%) | 137 | 65 (47.5%) | 0.26 |
Insulin therapy | 89 | 35 (39.3%) | 19 | 8 (42.1%) | 70 | 27 (38.6%) | 138 | 34 (24.6%) | 0.04 |
Vitamin K Antagonist | 89 | 64 (71.9%) | 19 | 11 (57.9%) | 70 | 53 (75.7%) | 138 | 37 (26.8%) | < 0.001 |
Fluindione | 64 | 44 (68.8%) | 11 | 6 (54.6%) | 53 | 38 (71.7%) | 37 | 18 (48.7%) | |
Warfarin | 64 | 17 (26.6%) | 11 | 3 (27.7%) | 53 | 14 (26.4%) | 37 | 16 (43.2%) | |
Corticosteroids | 89 | 10 (11.2%) | 19 | 2 (10.5%) | 70 | 8 (11.4%) | 138 | 16 (11.6%) | 0.97 |
Statin | 89 | 46 (51.7%) | 19 | 9 (47.4%) | 70 | 37 (52.7%) | 138 | 71 (51.5%) | 0.85 |
ESA | 89 | 72 (80.9%) | 19 | 9 (47.4%) | 70 | 63 (90.0%) | 137 | 106 (77.4%) | 0.03 |
Iron therapy | 89 | 63 (70.8%) | 19 | 8 (42.1%) | 70 | 55 (78.6%) | 137 | 102 (74.4%) | 0.51 |
ACEi/ARB | 89 | 32 (36.0%) | 19 | 8 (42.1%) | 70 | 24 (34.3%) | 138 | 43 (31.2%) | 0.65 |
Hemodialysis parameters | |||||||||
HD | 67 | 43 (64.2%) | 138 | 91 (65.9%) | |||||
HDF | 67 | 47 (34.1%) | 138 | 24 (35.8%) | |||||
eKt/V | 62 | 1.40 (1.06–1.67) | 131 | 1.53 (1.33–1.82) | < 0.001 | ||||
Citrate | 67 | 10 (14.3%) | 138 | 20 (14.3%) | 1.00 |